Investors and Media 

Lirum Therapeutics Invited to Present at Prestigious Gordon Research Conference

​

New York, NY – March 19, 2025 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that the Company has been invited to present at the renowned Gordon Research Conference Meeting on March 19th in Ventura, California...

Lirum Therapeutics Announces Debut of LX-101 Results in Thyroid Eye Disease, Selected for Presentation at the 2025 NANOS Annual Meeting

​

New York, NY – March 17, 2025 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that its first data on LX-101 in Thyroid Eye Disease (TED) have been selected for presentation at the 51st Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS)...

Lirum Therapeutics Presents Positive Data on LX-101 at the 2025 ESMO Targeted Anticancer Therapies Congress; Highlighting LX-101’s Promise in IGF-1R Prominent Cancers

​

New York, NY – March 4, 2025 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the presentation of additional positive data on LX-101 at the 2025 ESMO Targeted Anticancer Therapies Congress (TAT) in Paris, France. LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R)...

Lirum Therapeutics to Present Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity, at the 2024 AACR Annual Meeting

​

New York, NY – April 4, 2024 – Lirum Therapeutics, Inc. ("Lirum"), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced the upcoming presentation of positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), at the American Association for Cancer Research Annual Meeting...

Lirum Therapeutics Announces Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy, at the 2024 ESMO Sarcoma and Rare Cancers; Demonstrating Potent Preclinical Activity

​

New York, NY – March 14, 2024 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the acceptance for presentation of positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin-like growth factor 1 receptor (“IGF-1R”)...

Lirum Therapeutics Presents Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy, at the 2024 ESMO TAT; Highlighting LX-101’s Potential in IGF-1R Prominent Cancers

​

New York, NY – February 26, 2024 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that it will present positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin growth factor-1 receptor (IGF-1R)....

​

Lirum Therapeutics Participates in the 13th Annual LifeSci Partners Corporate Access Event 

​

New York, NY – January 9, 2024 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that management is participating in the 13th Annual LifeSci Partners Corporate Access Event, which is taking place January 8-10, 2024 ....

​

Lirum Therapeutics Presents Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against Pediatric Sarcomas 

​

New York, NY – October 31, 2023 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today announced the presentation of positive data at the 2023 Connective Tissue Oncology Society meeting in Dublin, Ireland....

Lirum Therapeutics to Present at the 2023 ThinkEquity Conference

​

New York, NY – October 19, 2023 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that Peter McDonald, the CEO of Lirum, will present at the 2023 ThinkEquity Conference on Thursday, October 19, 2023, at 2:00 PM ET. The conference will be held at the Mandarin Oriental Hotel in New York, NY.... 

Lirum Therapeutics Presents Data on LX-101, A Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against a Range of Pediatric Cancers

​

New York, NY – June 5, 2023 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today announced the presentation of positive data at the 7th Cancer World Congress in Palermo, Italy... 

Lirum Therapeutics Announces Closing of $7 Million Private Placement of Common Stock

​

New York, NY – February 8, 2023 – Lirum Therapeutics, Inc. (the “Company” or “Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today announced that it has closed a private placement, which resulted in gross proceeds to Lirum of over $7 million, before deducting offering expenses...